Biosimilar drugs are extremely identical to permitted on-going biologic drugs. “Copied” or approved copies of reference biological products under patented products are biosimilars or following-on-biologics. A critical part of the overall production process is the production and evaluation of bio-referential biologics. In the conservation of feasibility and consistency between initial and biosimilar goods the rules for biosimilars play an important role.
U.S Biosimilars Market: Competitive landscape
Biosimilar key players leverage advantages in orphan biosimilars. As inexpensive care choices for patients in need of biologics, biosimilars are growing rapidly. As new treatments are highly prevalent, corporations have a heightened aim to direct progress in biosimilars.
o Company Overview
o Business Strategy
o Key Product Offerings
o Financial Performance
o Key Performance Indicators
o Risk Analysis
o Recent Development
o Regional Presence
o SWOT Analysis
- Coherus Biosciences
- Merck & Co.
- Teva Pharmaceutical Industries
- STADA Arzneimittel
- Other prominent players
A growing number of patients affected by such illnesses would result in an increased incidence of chronic diseases throughout the world, in particular in developed countries, due to the increased sedentary lifestyle and the increasing practice of fast-food consumption.
U.S Biosimilars Market: Segments
U.S market has been segmented on the basis of Product type, application, and by location. It has been further segmented by countries into Northern, Eastern, western and southern region.
By Product type (in %), U.S Biosimilars Market, 2019
Recombinant non-glycosylated proteins segment is anticipated to register high volume share.
On the basis of product type the biosimilars market is segmented into: Recombinant non-glycosylated proteins and Recombinant glycosylated proteins. Recombinant non-glycosylated proteins are further segmented into human growth hormone, granulocyte colony-stimulating factor, insulin and interferon. The Recombinant non-glycosylated proteins market held a market share of XX% in the year 2019 and is expected to grow at fastest pace during the forecast period due to technological developments in cell technology and high-throughput logical methods are likely to facilitate efficient manufacturing of recombinant non-glycosylated proteins leading to improved sales.
U.S Biosimilars Market: Market Dynamics
Cost-Effectiveness to increase the demand for the market
With the lifestyle becoming a more sedentary and the growing number of people affected by chronic diseases, there needs to be an emphasis on reducing healthcare costs. Biosimilars are likely to play a crucial role as they are cost-effective and will save a huge amount of money becoming easily affordable for the general public.
Huge costs involved are expected to hinder the market demand
In the less-developed and emerging nations, enormous costs associated with the production of bio-similar drugs would likely hinder progress. In the lack of strict legislation, consumer commitment to a brand, doctors’ inability to prescribe biosimilars and others, the growth of the biosimilars market is further hindered by the lack of customers’ loyalty.
U.S Biosimilars Market: Region
U.S to hold the largest market share during the forecast period
U.S accounted for major share during 2019 and is estimated to dominate the biosimilars market. The American market is to be propelled due to the prevalence of key research & development centers. Moreover, US being the most developed and economically stable nation and major players belonging to the state are supposed to boost the overall growth in the development of biosimilars. Asia-Pacific is anticipated to register a healthy growth rate during the forecast period due to increasing geriatric population, ill-eating habits of the millennial, rising consumption of tobacco and alcohol. These factors are to fuel the overall market growth.
The region segment can be further divided into four major types including Eastern US, Northern US, Western US and Southern US.
U.S Biosimilars Market: Impact of COVID-19
There are many experimental regimens world-wide to try to find suitable for Covid-19. Hydroxychloroquine is used in one category of therapies, while antiviral drugs used in treating HIV are included in a second method for cure. The market for specialized antivirals and antimalarials has increased demand for both of these methods. The pharmaceutical companies must also be viewed as an indicator of the off-label for these drug groups.
U.S Biosimilars Market Report also contains an analysis on:
U.S Biosimilars Market by segment:
- By Product Type
o Recombinant Non-Glycosylated Proteins
o Human Growth Hormone
o Granulocyte Colony-Stimulating Factor
o Recombinant Glycosylated Proteins
o Monoclonal Antibodies
o Low Molecular Weight Heparin
- By Application
o Autoimmune Disease
o Growth Hormone Deficiency
- By Manufacturer
o In-house Manufacturing
o Contract Manufacturing
US Biosimilars Market Dynamics
US Biosimilars Market Size
Supply & Demand
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Table of Content
- Executive Summary
- Global Nerve Repair and Regeneration Market
- Average Pricing Analysis
- Macro-Economic Indicators
- Market Dynamics
- Correlation & Regression Analysis
- Recent Development, Policies & Regulatory Landscape
- Risk Analysis
- Global Nerve Repair and Regeneration Market
- Global Nerve Repair and Regeneration Market: Market Segmentation
13 Company Profile
Read Other Reports from our Database :
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)